12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Clinigen Group, Novartis sales and marketing update

Clinigen acquired Cardioxane dexrazoxane from Novartis for $33 million in cash, which will be paid in two tranches. Clinigen said it plans to "revitalize" the product...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >